Hana Biosciences Announces $12.4 Million Private Placement
October 08, 2009 07:05 ET
|
Talon Therapeutics, Inc.
* Financing led by OrbiMed Advisors LLC, Perceptive Life Sciences
Master Fund Ltd., Quogue Capital LLC and Deerfield Management
* Proceeds to be used to advance Hana's lead clinical compound
...
Hana Biosciences Enters Into Clinical Trial Agreement With the National Cancer Institute for Development of Marqibo(R) in Pediatric Cancer
September 30, 2009 07:05 ET
|
Talon Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 30, 2009 (GLOBE NEWSWIRE) -- Hana Biosciences (OTCBB:HNAB) today announced that the Company has entered into a Clinical Trial Agreement (CTA) with the Center for...
Hana Biosciences Receives NASDAQ Delisting Notification
September 08, 2009 19:33 ET
|
Talon Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 8, 2009 (GLOBE NEWSWIRE) -- Hana Biosciences (Nasdaq:HNAB) today announced that the Company received a letter from the Staff of The NASDAQ Stock Market indicating...
Hana Biosciences Announces Second Quarter 2009 Results
August 14, 2009 17:45 ET
|
Talon Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 14, 2009 (GLOBE NEWSWIRE) -- Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced...
Hana Biosciences Reaches Patient Enrollment Target for Pivotal rALLy Clinical Trial of Marqibo in Acute Lymphoblastic Leukemia
August 12, 2009 07:05 ET
|
Talon Therapeutics, Inc.
56th Subject Enrolled and Dosed
Data Presentation Targeted for 2009 ASH Annual Meeting
NDA Submission Targeted for First Half of 2010
SOUTH SAN...
Hana Biosciences Presents Updated Marqibo Data At the American Society of Clinical Oncology Annual Meeting
June 02, 2009 06:30 ET
|
Talon Therapeutics, Inc.
* 30% CR/CRi Rate in First 33 rALLy Subjects
* rALLy Study Expected to Reach Target Enrollment by Mid-Year
* Encouraging Survival in Metastatic Uveal Melanoma Trial
SOUTH SAN FRANCISCO,...
Hana Biosciences Announces First Quarter 2009 Results
May 15, 2009 07:05 ET
|
Talon Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., May 15, 2009 (GLOBE NEWSWIRE) -- Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced...
Hana Biosciences Receives Going Concern Qualification
April 09, 2009 17:53 ET
|
Talon Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., April 9, 2009 (GLOBE NEWSWIRE) -- Hana Biosciences, Inc., (Nasdaq:HNAB), a biopharmaceutical company focused on developing and commercializing new, differentiated cancer...
Hana Biosciences Reports Fourth Quarter and Full Year 2008 Results
March 31, 2009 16:05 ET
|
Talon Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., March 31, 2009 (GLOBE NEWSWIRE) -- Hana Biosciences Inc., (Nasdaq:HNAB), a biopharmaceutical company focused on developing and commercializing new, differentiated cancer...
Hana Biosciences to Report Fourth Quarter and Full Year 2008 Financial Results On March 31, 2009
March 18, 2009 07:30 ET
|
Talon Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., March 18, 2009 (GLOBE NEWSWIRE) -- Hana Biosciences (Nasdaq:HNAB) will announce its fourth quarter and full year 2008 results on Tuesday, March 31, 2009, after the close...